Bicycle Therapeutics (BCYC) Set to Post Quarterly Earnings on Thursday

Bicycle Therapeutics (NASDAQ:BCYC) is anticipated to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.3990) per share and revenue of $12.22 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 6:00 AM ET.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.14). The firm had revenue of $0.63 million for the quarter, compared to analyst estimates of $4.22 million. On average, analysts expect Bicycle Therapeutics to post ($2.26) EPS for the current fiscal year and ($2.27) EPS for the next fiscal year.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $3.78 on Wednesday. The firm has a 50 day simple moving average of $3.85 and a 200-day simple moving average of $4.62. Bicycle Therapeutics has a one year low of $3.33 and a one year high of $9.08.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Needham & Company LLC reduced their target price on shares of Bicycle Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Zacks Research downgraded shares of Bicycle Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a research report on Friday, October 2nd. Finally, Wall Street Zen raised Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 15th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $13.86.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a biopharmaceutical company that develops medicines using its proprietary Bicycle molecule technology. Bicycle molecules are small, constrained peptides designed to bind selectively to biological targets while offering characteristics that may support tissue penetration, rapid clearance, and chemical synthesis. The company is primarily focused on creating therapies for cancer and other serious diseases.

Bicycle Therapeutics’ research programs include targeted therapeutics intended to deliver cytotoxic payloads to tumor cells, as well as immune-modulating treatments designed to activate or direct the immune system within the tumor microenvironment.